- Home
- RAC vs PROF Comparison
RAC vs PROF Comparison
Compare RAC & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RAC | PROF |
|---|---|---|
| Founded | 2024 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 310.3M | 248.8M |
| IPO Year | 2025 | 2017 |
Fundamental Metrics
Financial Performance| Metric | RAC | PROF |
|---|---|---|
| Price | $10.59 | $7.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.14 |
| AVG Volume (30 Days) | 99.3K | ★ 200.1K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | N/A | $69.27 |
| Revenue Next Year | N/A | $59.62 |
| P/E Ratio | $35.57 | ★ N/A |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $10.29 | $4.91 |
| 52 Week High | $10.61 | $8.95 |
Technical Indicators
Market Signals| Indicator | RAC | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 54.70 | 71.20 |
| Support Level | $10.54 | $6.51 |
| Resistance Level | N/A | $7.92 |
| Average True Range (ATR) | 0.01 | 0.46 |
| MACD | 0.00 | 0.19 |
| Stochastic Oscillator | 60.12 | 92.86 |
Price Performance
Historical ComparisonAbout RAC Rithm Acquisition Corp. Class A Ordinary Shares
Rithm Acquisition Corp is a blank check company.
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.